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Abstract 
Purpose Cilostazol (Pletal), a phosphodiesterase-3 inhi- bitor, was approved in the United States in 1999 to 
reduce symptoms of intermittent claudication. Cyclic adenosine monophosphate levels increase from inhibition 
of phos- phodiesterase resulting in anti-platelet, anti-inﬂammatory, and vasodilatory effects. Diabetes mellitus 
is a chronic disease that causes endothelial and platelet dysfunction leading to both microvascular and 
macrovascular compli- cations. This mini-review highlights the emerging evidence suggesting beneﬁts of using 
cilostazol in treating micro- vascular complications associated with diabetes mellitus. Methods A review of 
literature was conducted using PubMed and Embase databases focusing on cilostazol use in diabetes mellitus. 
Results Cilostazol demonstrated renoprotective effects in patients with diabetic nephropathy by reducing serum 
soluble adhesion molecule-1 and monocyte chemoattractant protein-1. Cilostazol’s anti-inﬂammatory actions 
predictably attenuate glomerular damage from increased leukocyte adherence. Additionally, cilostazol delayed 
renal dysfunc- tion secondary to type 2 diabetes mellitus as albuminuria was reduced most likely resulting from 
inhibition of nuclear factor kappa-induced inﬂammatory and endothelial mar- kers. Cilostazol’s anti-
inﬂammatory actions in addition to its vasodilatory actions relieved retinal hypoxia and decreased excessive 
production of retinal blood vessels suggesting beneﬁt in diabetic retinopathy. Cilostazol did not   improve 
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neuropathy symptom scores signifying that it may not be as beneﬁcial in patients with diabetic peripheral 
neuropathy without diabetic nephropathy or diabetic retinopathy. 
Conclusions Cilostazol’s pleiotropic effects may be bene- ﬁcial in patients with type 2 diabetes mellitus and 
diabetic nephropathy. Additional, larger studies need to be con- ducted to assess the beneﬁts and risks of 
using cilostazol as an alternative agent in treating patients with diabetic microvascular complications. 
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Introduction 
 
Cilostazol (Pletal), a phosphodiesterase-3 inhibitor, was approved in the United States in 1999 to reduce 
symptoms of intermittent claudication. Prior to its approval in the United States market, cilostazol was 
registered for 10 years in Japan [1]. Its off-label uses include secondary prevention of cerebrovascular 
accident, coronary stent stenosis, and percutaneous coronary intervention. Patients with diabetes mellitus 
have elevated platelet reactivity and cilostazol, combined with aspirin and clopidogrel, has been found to be 
more effective in secondary prevention of cerebral infarction than aspirin and clopidogrel alone [2]. 
Compared with other antiplatelet agents, cilostazol was found to inhibit carotid intima-media thickness 
progression in patients with type 2 diabetes mellitus, and therefore may be helpful in controlling carotid 
atherosclerosis [3]. 
Phosphodiesterase (PDE) enzymes are grouped into eleven broad families, PDE-1 to PDE-11, based on 
their various properties and structures. PDE-3 inhibitors can be further subdivided into PDE-3As and PDE-
3Bs. PDE-3As are found in platelets, vascular smooth muscle cells, and cardiac myocytes, while PDE-3Bs are 
found in adipocytes, hepatocytes, pancreatic β cells, and macrophages [4]. By inhibiting PDEs, cyclic 
adenosine monophosphate levels increase resulting in pleiotropic effects such as anti-platelet, anti-
inﬂammatory, and vasodilatory effects. 
Diabetes mellitus is a chronic disease that causes endo- thelial and platelet dysfunction [5]. Endothelial 
dysfunction develops with disease progression leading to both macro- vascular and microvascular 
complications. Reduced angio- genesis in the brain, heart, and legs leads to macrovascular complications, 
whereas excessive angiogenesis in the eye, kidney, and nerves causes microvascular complications [6]. 
Nontraditional uses of cilostazol have been explored as PDE-3s are found extensively throughout the body. 
This mini-review highlights the emerging evidence suggesting beneﬁts of using cilostazol in treating 
microvascular com- plications associated with diabetes mellitus. 
 
 
 
Diabetic nephropathy 
 
Diabetic nephropathy can cause end-stage renal disease and is characterized by proteinuria with early increases 
in urinary albumin levels [7, 8]. Reactive oxygen species, induced by hyperglycemia, cause both direct and 
indirect endothelial damage by modifying extracellular matrix pro- teins and by escalating the inﬂammatory 
response [9, 10]. Nuclear factor kappa B is triggered by reactive oxygen species and induces monocyte 
chemotactic protein-1 (MCP- 1), a pro-inﬂammatory chemokine, which contributes to renal deterioration by 
recruiting macrophages [11–14]. 
In a randomized, placebo-controlled trial, cilostazol was evaluated in 90 Taiwanese patients with diabetic 
nephro- pathy and peripheral arterial occlusion disease [15]. The effects of cilostazol in delaying renal 
dysfunction secondary to type 2 diabetes mellitus were assessed through changes in urinary microalbuminuria 
(MAU) and albumin-to-creatinine ratio (ACR). Only patients with type 2 diabetes mellitus with an A1C 
between 7.0 and 12.0% were included in the study and were given either oral cilostazol 100 mg twice daily (n 
 
  
= 45) or placebo (n = 45) for 52 weeks. Partici- pants were subdivided into two groups based on baseline 
values: MAU (ACR 30–300 μg/mg) or macroalbuminuria (ACR > 300 μg/mg). The average age, duration of 
diabetes, and baseline A1C values were similar between groups. Patients in the cilostazol-treated group had a 
greater body- mass index, were more likely to smoke, and more likely to take statins, ACE-Is/ARBs, and 
aspirin. After 52 weeks of treatment, cilostazol reduced albuminuria (p = 0.024) and subsequently reduced the 
ACR (p = 0.02) compared with placebo; however, the values were only marginally reduced in patients with   
MAU (p = 0.06)   after   subdivision.  A regression analysis found that changes in albuminuria and ACR were 
associated with notable changes in inﬂammatory and endothelial markers, suggesting that cilostazol exhibits 
protective effects through its anti-inﬂammatory actions. Treatment with cilostazol signiﬁcantly reduced the 
inﬂam- matory marker highly-sensitive C-reactive protein (p = 0.03), endothelial markers E-selectin (p < 
0.001) and solu- ble vascular cell adhesion molecule-1 (p < 0.001). Results of the study suggest that renal 
deterioration resulting from an upregulated immune response mediated by NF-ĸB-induced inﬂammatory and 
endothelial markers may be suppressed with cilostazol by inhibiting NF-ĸB [15–17]. Additionally, as 
supported by another study, cilostazol may ameliorate peripheral arterial occlusion disease, a macro- vascular 
complication of diabetes mellitus, in patients with type 2 diabetes mellitus by attenuating pro-inﬂammatory 
markers [18]. 
The renoprotective effects of cilostazol in diabetic nephropathy were demonstrated in another study [19]. 
Jiao et al. measured changes in serum soluble adhesion molecule-1 (sICAM-1) and MCP-1 levels in patients 
with type 2 diabetes mellitus with and without early diabetic nephropathy. Early nephropathy was deﬁned as 
a urinary albumin excretion rate level between 30 and 300 mg/24 h. Participants were divided into three 
groups with the ﬁrst group (Group A) consisting of 20 subjects without protei- nuria. Forty participants with 
early diabetic nephropathy were evenly divided into the second (Group B) and third groups (Group C). 
Subjects in Group B received cilostazol 100 mg twice daily, while subjects in Group C received placebo. 
Treatment lasted for 6 months and participants were not to take aspirin, other antiplatelet agents, antic- 
oagulants, or vasodilators during the study period. Prior to the start of the study, the sICAM-1 levels in the 
three groups were: Group A 214.5 + 94.6 ng/mL, Group B 450.0 
+ 100.7 ng/mL,    and    Group    C  422.0 + 422.9 ng/mL. 
Patients with early diabetic nephropathy had higher baseline levels of sICAM-1, suggesting that the 
occurrence of dia- betic nephropathy is associated with increased levels of sICAM-1 causing glomerular 
damage from increased leu- kocyte adherence [20, 21]. After treatment with cilostazol, sICAM-1, MCP-1, 
and urinary albumin excretion rate decreased signiﬁcantly (sICAM-1 285.1 + 94.4, p < 0.01) compared with 
treatment with placebo (sICAM-1 412.3 + 89.6). Additional measures in the study included blood pressure, 
liver and kidney function, and HbA1c; however, no signiﬁcant changes were observed after treatment with 
cilostazol. 
Together, the results from both studies demonstrate that the proposed mechanism of action by which 
cilostazol ameliorates the progression of renal dysfunction in patients with diabetic nephropathy is through 
reduced inﬂammation.
 
 
 
Diabetic retinopathy 
 
Diabetes-induced retinal neurodegeneration results from increased vascular permeability and disordered retinal angiogenesis 
[7]. Glucose toxicity causes endothelial dys- function, which increases permeability allowing circulating macrophages and 
pro-inﬂammatory cytokines to enter and cause neuronal damage [22]. Both hyperglycemia and hypoxia damage the 
endothelium by triggering cells to produce signal proteins such as vascular endothelial growth factor (VEGF) [23, 24]. 
Current treatments for diabetic retinopathy focus on inhibiting VEGF since overproduction results in disordered 
angiogenesis [25]. However, reducing rather than blocking VEGF may be an alternative strategy since VEGF initially 
protects cells by re-establishing oxy- gen delivery [25]. 
In a preclinical study performed in rats, the effects of oral cilostazol (30 mg/kg) on retinal neurodegeneration were 
compared with 0.9% saline solution [24]. Diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats and matched 
nondiabetic Long-Evans Tokushima Otsuka (LETO) control rats were treated daily for 15 weeks with either cilostazol or 
placebo. Glial ﬁbrillary acidic protein immunostaining and VEGF immunoreactivity demonstrated that cilostazol treat- ment 
improved retinal stress and ischemia, respectively. Retinal glial ﬁbrillary acidic protein and VEGF protein levels decreased 
in both OLETF and LETO rats with cilostazol treatment; however, levels decreased signiﬁcantly only in OLETF rats. 
Cilostazol was also able to signiﬁcantly reduce retinal ganglion cell death in OLETF diabetic rats, suggesting that it may 
protect against diabetic retinopathy. 
As demonstrated in the study, cilostazol’s vasodilatory properties relieve hypoxia by improving ischemia and its anti-
inﬂammatory properties reduce excessive production of blood vessels by decreasing VEGF expression. Human studies need 
to be conducted to support these results to further evaluate cilostazol’s effect in protecting against neuronal damage and 
prevent vision loss in patients with diabetes. 
 
Diabetic neuropathy 
 
In a small pilot study, cilostazol (100, 200 mg/day) was compared with placebo to evaluate changes in neuropathy symptom 
scores (NSS) in Filipino patients with type 2 diabetes mellitus and with diabetic peripheral neuropathy [26]. Neuropathy was 
diagnosed through the accordance of two neurologists and was assessed by comparing patient- reported NSS taken at 
baseline, week 4, week 8, and  week 
12. Additionally, walking distance and walking speed were assessed using a Walking Impairment Questionnaire. Patients 
were divided into three groups: 15 patients treated with placebo, 16 patients treated with cilostazol 100 mg/day, 
 
  
and 16 patients treated with cilostazol 200 mg/day. Patients included in the study were diagnosed with type 2 diabetes 
mellitus more than 3 months prior to start of the trial, were in good glycemic control (HbA1c ≤ 8%), and were maintained on 
their diabetes medications during the study period. The mean age between treatment groups was 56 years with a greater 
proportion of women in each treatment group. Patients in the placebo-treated group were on average hea- vier, while 
patients in the low-dose cilostazol treatment group were diagnosed with diabetes for a longer period of time. Although 
overall NSS did improve from baseline    to 
12 weeks, there were no signiﬁcant differences in NSS between treatment groups (at 12 weeks, p = 0.333). Walking speed 
improved signiﬁcantly (p = 0.028) with low-dose cilostazol treatment suggesting improved peripheral blood ﬂow. The 
most common reported adverse events at week 4 were headaches (12 patients) and palpitations (8 patients); however, these 
side effects were not reported at week 12 of the study. Out of the 12 patients that reported headaches, three were receiving 
placebo, four were receiving low-dose cilostazol, and ﬁve were receiving high-dose cilostazol. Results from this study did 
not demonstrate signiﬁcant improvement in relieving the symptoms of diabetic neuro- pathy with cilostazol therapy. 
However, increased walking speed in the low dose-treated cilostazol group suggests potential beneﬁt in patients with 
diabetes. 
 
Adverse reactions 
 
In the trials reviewed above, cilostazol did not change body mass index, hemoglobin A1c, fasting glucose, and ankle- 
brachial index [8, 15, 24, 26]. Since blood glucose levels were not improved, good glycemic control in patients with 
diabetes is essential and is likely the rationale for appro- priate glycemic control as an inclusion criterion [15, 26]. In the 
Tang et al. study, two patients withdrew due to severe dizziness in the cilostazol-treated group, while in the Rosales et al. 
study patients treated with cilostazol experi- enced more headaches and palpitations, however, these side effects 
disappeared after week 8 [26]. The risks and beneﬁts of initiating and continuing cilostazol should be evaluated for each 
patient especially in patients with a history of angina, cardiac arrhythmias, and uncontrolled hypertension [27]. Dizziness, 
headaches, and palpitations are common adverse reactions related to cilostazol as well as are diar- rhea, pharyngitis, and 
rhinitis [27]. Furthermore, because of cilostazol’s potential to induce palpitations and tachyar- rhythmia, its use is 
contraindicated in patients with con- gestive heart failure [27]. Serious adverse reactions include atrial ﬁbrillation, cardiac 
arrest, myocardial infarction, and ventricular tachycardia, as well as bleeding and hemorrha- ging [27]. In a case report 
including three patients, a potential       relationship       between     cilostazol-induced 
 
 
  
tachycardia and hyperglycemia was observed [28]. All three patients had a past medical history of type 2 diabetes and were 
admitted for cerebral infarction. Cilostazol was initiated in each patient to prevent a subsequent cerebral infarction. All three 
patients had an elevated HbA1c and included an HbA1c of 10.7, 10.3, and 9.3% upon admission for patients 1, 2, and 3, 
respectively. Two out of the three patients were switched from cilostazol to clopidogrel as their heart rates increased 
following cilostazol initiation. Notable decreases in heart rate and blood glucose were noted in both patients following drug 
substitution. Patient 2 beneﬁted from an increase in heart rate as he had sinus bradycardia with ﬁrst degree atrioventricular  
block and therefore continued cilos- tazol. The effects of cilostazol on glycemic control require further investigation as the 
studies above did not show a change in fasting glucose and hemoglobin A1c. However, all patients included in the studies had 
good glycemic control unlike the three patients included in the case report. For patients without good glycemic control, 
cilostazol initiation may not be appropriate and if initiated, then close monitoring to adjust diabetes medications may be 
necessary. 
 
 
Conclusion 
 
Cilostazol shows potential beneﬁt in treating microvascular diabetic complications such a diabetic nephropathy. It is 
important to keep in mind that most of the clinical studies evaluating cilostazol’s effects were conducted primarily in Asian 
populations with a small number of subjects. While evidence exists, further studies in more diverse, human populations need 
to be conducted to fully evaluate cilosta- zol’s therapeutic potential in ameliorating diabetic micro- vascular complications. 
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